CIP2A expression and localization in oral carcinoma and dysplasia

Cancer Biology and Therapy

Volumn 10, Issue 7, 2010, Pages 694-699

  Katz, Joseph ^a   Jakymiw, Andrew ^a   Ducksworth, Monet K ^a   Stewart, Carol M ^a   Bhattacharyya, Indraneel ^a   Cha, Seunghee ^a   Chan, Edward K L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

Author keywords

C MYC; CIP2A; Dysplasia; EGFR; Oral cancer

Indexed keywords

AUTOANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PROTEIN CANCEROUS INHIBITOR OF PP2A; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DYSPLASIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

AUTOANTIGENS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELLS, CULTURED; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MOUTH DISEASES; MOUTH NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77957604773     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.7.12895     Document Type: Article

References (18)

1. Jamel A, Siegel R, Ward D, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. Ca Cancer J Clin 2009; 59:225-49.
2. Lingen MW. Pragmatics versus contrarians: how does one resolve their differences with respect to oral cancer screening? Oral Surg, Oral Medicine, Oral Path 2010; 3:325-6.
3. Stewart SL, Cardinez CJ, Richardson LC, Norman L, Kaufmann R, Pechacek TF, et al. Surveillance for cancers associated with tobacco use - United States 1999-2004. MMWR Surveill Summ 2008; 57:1-33.
4. Campana JP, Meyers AD. The surgical management of oral cancer. Otolaryngol Clin North Am 2006; 39:331-48.
5. Fedele S. Diagnostic aids in the screening of oral cancer. Head Neck Oncol 2009; 30:1-5.
6. Warnakulasuriya S, Rebel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive values, utility, weaknesses and scope for improvement. J Ortal Pth Med 2008; 37:127-33.
7. Fischer DJ, Epstein JB, Morton TH, Schwartz SM. Interobserver reliability in the histopathologic diagnosis of oral pre-malignant and malignant lesions. J Oral Path Med 2004; 33:65-70. (Pubitemid 38166425)
8. Kujan O, Khattab A, Oliver RJ, Roberts SA, Thakker N, Sloan P. Why oral histopathology suffers interobserver variability on grading oral epithelial dysplasia: an attempt to understand the sources of variation. Oral Oncol 2007; 43:224-31.
9. Hiraishi Y, Wada T, Nakatani K, Negoro K, Fujita S. Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas. Pathol Oncol Res 2006; 12:87-91.
10. Laimer K, Spizzo G, Gastl G, Obrist P, Brunhuber T, Fong D, et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncology 2007; 43:193-8.
11. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol 2010; 17:37-48.
12. Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 2002; 21:5006-15.
13. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A Inhibits PP2A in Human Malignancies. Cell 2007; 130:51-62.
14. Westermarck J, Hahn W. Multiple Pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14:152-60.
15. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, et al. CIP2A is overexpressed in gastric cancer and Its depletion leads to impaired clonogenicity, senescence or differentiation of tumor cells. Clin Cancer Res 2008; 14:3722-8.
16. Juntila MR, Westermarck J. Mechanism of MYC stabilization in human malignancies. Cell Cycle 2008; 7:592-6. (Pubitemid 351498996)
17. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu Z, et al. CIP2A is associated with human cancer aggressivity. Clin Cancer Res 2009; 15:5092-100.
18. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009; 101:793-805